AlOmeir Othman, Patel Nilesh, Donyai Parastou
Department of Pharmacy, University of Reading, Reading, Berkshire, UK.
Patient Prefer Adherence. 2022 Sep 23;16:2639-2647. doi: 10.2147/PPA.S368636. eCollection 2022.
Non-adherence to adjuvant hormone therapy prescribed orally in the treatment of breast cancer is complex as the literature has shown. Many women find it hard to adhere to the hormonal medicines they are prescribed and expected to take for at least 5 years following the initial management of their breast cancer. Arguably, communicating other women's 'trials, tribulations, and triumphs' with medication-taking could help newly-diagnosed patients to better prepare for the journey ahead. Our objective was to visually represent women's experiences with these medicines using data synthesized in the literature.
Three schematics were drawn for each phase of medication-taking, namely, starting out, adherence, and cessation. The schematics were validated by interviewing a panel of healthcare professionals (n=10) and calculating a Content Validity Index (CVI). The edited drawings were discussed with a separate panel of breast cancer survivors (n=14) whose responses were elicited qualitatively in one-to-one interviews.
A total of 76 individual pictograms were drawn across the three schematics. The 13 pictograms that had an item-level CVI<0.8 were modified according to feedback resulting in three final schematics with an overall CVI of 87%, 87% and 80%, respectively.
Synthesised summaries of women's experiences with oral hormone therapy for breast cancer were visualised via three validated schematics. The schematics could aid patient-professional communication to help anticipate and tackle negative experiences and support decisions to take hormone medication in breast cancer.
正如文献所示，在乳腺癌治疗中，患者对口服辅助激素治疗的依从性情况较为复杂。许多女性发现，很难坚持服用她们所 prescribed 的激素药物，且在乳腺癌初始治疗后需要服用至少5年。可以说，分享其他女性在服药过程中的“尝试、磨难和成功”，有助于新确诊的患者更好地为未来的治疗过程做好准备。我们的目的是利用文献中综合的数据，直观呈现女性使用这些药物的经历。
针对服药的每个阶段，即开始服药、坚持服药和停药，绘制了三幅示意图。通过与一组医疗保健专业人员（n = 10）进行访谈并计算内容效度指数（CVI），对示意图进行了验证。与另一组乳腺癌幸存者（n = 14）讨论了编辑后的图纸，通过一对一访谈定性地收集了他们的回答。
在三幅示意图中总共绘制了76个单独的象形图。根据反馈意见，对13个项目水平CVI < 0.8的象形图进行了修改，最终得到三幅示意图，其总体CVI分别为87%、87%和80%。
通过三幅经过验证的示意图，直观呈现了女性在乳腺癌口服激素治疗方面的综合经验总结。这些示意图有助于医患沟通，帮助预测和应对负面经历，并支持乳腺癌患者服用激素药物的决策。
